Literature DB >> 14578247

Association of the p22phox component of NAD(P)H oxidase with susceptibility to diabetic nephropathy in patients with type 1 diabetes.

Andrea D Hodgkinson1, Beverley A Millward, Andrew G Demaine.   

Abstract

OBJECTIVE: Increased production of reactive oxygen species (ROS) in diabetes is thought to play a major role in the pathogenesis of diabetic microvascular complications such as nephropathy and retinopathy. The NAD(P)H oxidase complex is an important source of ROS in the vasculature. The p22 subunit is polymorphic with a C242T variant that changes histidine-72 for a tyrosine in the potential heme binding site, together with a A640G in the 3' untranslated region. The aim was to investigate the frequency of these polymorphisms in 268 patients with type 1 diabetes with or without microvascular complications. RESEARCH DESIGN AND METHODS: There was a highly significant increase in the frequency of the T/T242 genotype in patients with nephropathy compared with those with retinopathy alone or no microvascular disease after 20 years' diabetes duration (uncomplicated) or normal healthy control subjects (33.3 vs. 6.5, 5.7, and 0.0%, respectively, P < 0.000001). Furthermore, the T242/G640 haplotype was found in 39.4% of the patients with nephropathy but in only 26.5% of the patients with retinopathy and 15.3 and 10.6% of the uncomplicated and normal control subjects, respectively.
RESULTS: When these variants of NAD(P)H oxidase were analyzed together with aldose reductase (5'ALR2) susceptibility genotypes, >46.0% of the patients with nephropathy possessed a T242 allele with the Z-2 5'ALR2 allele compared with only 11.2% of the uncomplicated patients (P < 0.00003).
CONCLUSIONS: In conclusion, these results suggest NAD(P)H oxidase together with the polyol pathway may contribute to the pathogenesis of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578247     DOI: 10.2337/diacare.26.11.3111

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  4 in total

1.  Haplotype analysis of NAD(P)H oxidase p22 phox polymorphisms in end-stage renal disease.

Authors:  Kent Doi; Eisei Noiri; Akihide Nakao; Toshiro Fujita; Shuzo Kobayashi; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2005-10-08       Impact factor: 3.172

2.  Association of genetic variants in the promoter region of genes encoding p22phox (CYBA) and glutamate cysteine ligase catalytic subunit (GCLC) and renal disease in patients with type 1 diabetes mellitus.

Authors:  Suzana M Vieira; Maria B Monteiro; Tatiana Marques; Ana M Luna; Maria A Fortes; Márcia Nery; Márcia Queiroz; Sérgio A Dib; Márcio F Vendramini; Mirela J Azevedo; Luis H Canani; Maria C Parisi; Elizabeth J Pavin; Daniel Giannella-Neto; Maria L Corrêa-Giannella
Journal:  BMC Med Genet       Date:  2011-09-30       Impact factor: 2.103

3.  p22phox C242T gene polymorphism and overt diabetic nephropathy: a meta-analysis of 1,452 participants.

Authors:  Yan-Yan Li; Ge Gong; Hong-Yu Geng; Yun Qian
Journal:  Korean J Intern Med       Date:  2016-12-08       Impact factor: 2.884

4.  Association of the NAD(P)H oxidase p22 phox gene C242T polymorphism with type 2 diabetes mellitus, diabetic nephropathy, and carotid atherosclerosis with type 2 diabetes mellitus: A meta-analysis.

Authors:  Tao Li; Hai-Feng Xi; Hong-Min Luo; Wen-Xuan Liu; Xia Gao; Dian-Wu Liu; Lei Yang
Journal:  Meta Gene       Date:  2015-08-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.